<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aims:  Skin autofluorescence is a non-invasive marker of advanced glycation end product accumulation </plain></SENT>
<SENT sid="1" pm="."><plain>In a previous study, skin autofluorescence correlated with and predicted micro- and macrovascular complications in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a primary care setting </plain></SENT>
<SENT sid="2" pm="."><plain>The present cross-sectional study aims to confirm the association between skin autofluorescence and <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a multi-centre secondary care setting </plain></SENT>
<SENT sid="3" pm="."><plain>Methods:  We analysed 563 subjects with Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> from five Dutch hospitals </plain></SENT>
<SENT sid="4" pm="."><plain>Results:  Median age was 64 years, median duration of <z:mp ids='MP_0002055'>diabetes</z:mp> 13 years and median HbA(1c) 58 mmol/mol (7.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>Sixty-one per cent of patients had microvascular complications (38% <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, 36% <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, 35% <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>) and 42% had macrovascular complications </plain></SENT>
<SENT sid="6" pm="."><plain>Median UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study 10-year risk for coronary events was 19% </plain></SENT>
<SENT sid="7" pm="."><plain>Median skin autofluorescence was elevated compared with age-matched healthy control subjects: 2.77 (interquartile range 2.39-3.28) vs. 2.46 (2.08-2.84) arbitrary units  </plain></SENT>
<SENT sid="8" pm="."><plain>Skin autofluorescence was particularly increased in patients with complications: no complications, median 2.56 (2.26-2.90); microvascular complications, 2.79 (2.38-3.29); macrovascular complications, 2.85 (2.41-3.41); both micro- and macrovascular complications, 2.96 (2.56-3.60) arbitrary units, P &lt; 0.001 </plain></SENT>
<SENT sid="9" pm="."><plain>Logistic regression analysis showed that age, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, renal function, gender, <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and skin autofluorescence were independently associated with macrovascular complications </plain></SENT>
<SENT sid="10" pm="."><plain>Multiple regression analysis identified age, smoking, renal function, macrovascular complications and the number of microvascular complications as the determinants of skin autofluorescence </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusions:  This study confirms that skin autofluorescence is increased in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a secondary care setting </plain></SENT>
<SENT sid="12" pm="."><plain>Skin autofluorescence was associated with macrovascular complications in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and this association was independent of classical risk factors. © 2012 The Authors </plain></SENT>
<SENT sid="13" pm="."><plain>Diabetic Medicine © 2012 <z:mp ids='MP_0002055'>Diabetes</z:mp> UK </plain></SENT>
</text></document>